Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of mFOLFIRINOX vs mFOLFOX in high-risk stage III colon cancer (adjuvant)
2016-001491-29Phase 3Active
- Sponsor
- Unicancer
- Start
- Nov 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of irinotecan, oxaliplatin, fluorouracil and folinic acid in colon cancer (2 arms), sponsored by Unicancer. Primary endpoint: Disease-free survival at 3 years. Started Nov 2016; status: active.
02
Drugs
irinotecanoxaliplatinfluorouracilfolinic acid
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2016-001491-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001491-29.